A Phase 3 interventional study of Apremilast tablet 20 mg and Apremilast tablet 30 mg BID in Ankylosing Spondyloarthritis, sponsored by Amgen. Completed at 103 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-05-12.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Spondylitis, Ankylosing with a site in United States — 10 open to participants now, 13 under way, none of them phase 3. Spondylitis, Ankylosing · United States.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, this one is the 8th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2012, is one of 25 in phase 3, and was the 25th registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.
Browse Spondylitis, Ankylosing studies →10 of the 87 studies in Spondylitis, Ankylosing with a site in United States are open now. Recruiting first, the newest first:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Sites in United States
Ages 9–85 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18+
University of Central Florida · Sites in United States
Ages 18–65
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
AndHealth · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 19 · Phase 3 25 · Phase 4 3
First in 1995; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 490 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 223 across the 59 interventional studies, 445 across the 28 observational. Of the 68 that completed or were terminated, 40 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 87 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Amgen has 3 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies in Spondylitis, Ankylosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04751396M.D. Anderson Cancer CenterTesting of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors | 2027-02-02 |
Add it to your calendar (.ics) → With an account.
Among the 87 studies in Spondylitis, Ankylosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Apremilast is a new, orally available, small molecule drug that specifically inhibits phosphodiesterase 4 (PDE4), an enzyme that modulates inflammatory cytokines. This clinical study tests whether apremilast can improve the signs and symptoms of ankylosing spondylitis.
Patients were randomized in a 1:1:1 ratio to placebo, apremilast 20 mg BID and apremilast 30 mg BID. The duration of the study was approximately 5 years. The double blind period (when patients nor the physician knew whether placebo or apremilast was taken) was 24 weeks. At Week 16, participants who did not have either a ≥ 20% improvement or a ≥ 1 unit improvement from baseline in at least two of the four SpondyloArthritis international Society (ASAS) domains were entered in "early escape" from their current treatment in a double-blinded manner. However, such participants were permitted to continue in the study. At Week 24, participants may have entered a long-term extension phase for up to an additional 4.5 years (236 weeks). At "second escape" (at Week 24), apremilast 20 mg BID treated participants transitioned to receive double-blinded apremilast 30 mg BID and remained on double-blinded apremilast 30 mg BID because they continued to improve with a longer duration of treatment. After Week 24 and during the early portion of the long-term extension through Week 52, all participants continued on either double-blinded apremilast 20 mg BID or 30 mg BID treatment. After all participants had completed Week 52 or had terminated early from the study and the 52-week data base was locked, apremilast 20 mg BID or 30 mg BID treatment was provided.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Apremilast 20 mg was taken orally twice a day (BID)
Drug: Apremilast tablet 20 mg
Apremilast 30 mg was taken orally twice a day
Drug: Apremilast tablet 30 mg BID
Identically matched placebo tablets were taken orally twice a day
Drug: Placebo
Apremilast 20 mg was taken orally twice a day (BID)
Also known as: Otezla; CC-10004
Apremilast 30 mg was taken orally twice a day
Also known as: Otezla; CC-10004
Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
Time frame: Baseline and Week 16
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24
The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.
Time frame: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.
Time frame: Baseline and Week 24
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
Time frame: Baseline and Week 24
Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24
The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.
Time frame: Baseline and Week 24
Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement
Time frame: Baseline and Week 24
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24
The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.
Time frame: Baseline and Week 24
Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260
The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3. 0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.
Time frame: Baseline to Week 104 and 260
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.
Time frame: From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.
Time frame: Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks
The study enrolled participants at 88 study sites and in 18 countries (Australia, Austria, Bulgaria, Czech Republic, Estonia, France, Germany, Hungary, the Netherlands, Poland, Romania, Russia, Slovakia, Spain, the United Kingdom, Canada, Sweden, and the United States \[US\]).
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 30 mg Early Escape (EE) | Placebo/Apremilast 30 mg Crossover (XO) | Apremilast 30 mg /Apremilast 30 mg EE | Apremilast 20 mg /Apremilast 30 mg EE | Apremilast 30 mg /Apremilast 30 mg Second Escape (SE) | Apremilast 20 mg/Apremilast 30 mg SE |
|---|---|---|---|---|---|---|---|---|---|
| Started | 164 | 163 | 163 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received treatment | 164 | 163 | 163 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed week 16 | 150 | 151 | 144 | 0 | 0 | 0 | 0 | 0 | 0 |
| Early escape at week 16 | 51 | 49 | 49 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 145 | 147 | 138 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 19 | 16 | 25 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 6 | 7 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 2 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 3 | 5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 30 mg Early Escape (EE) | Placebo/Apremilast 30 mg Crossover (XO) | Apremilast 30 mg /Apremilast 30 mg EE | Apremilast 20 mg /Apremilast 30 mg EE | Apremilast 30 mg /Apremilast 30 mg Second Escape (SE) | Apremilast 20 mg/Apremilast 30 mg SE |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 74 | 65 | 47 | 91 | 48 | 48 | 25 | 23 |
| Completed | 0 | 69 | 61 | 41 | 85 | 43 | 43 | 22 | 21 |
| Not completed | 0 | 5 | 4 | 6 | 6 | 5 | 5 | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 1 | 2 | 0 | 1 | 1 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 6 | 3 | 2 | 5 | 1 | 2 |
| Withdrew: Non-compliance study drug | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0 |
| Milestone | Placebo | Apremilast 20 mg | Apremilast 30 mg | Placebo / Apremilast 30 mg Early Escape (EE) | Placebo/Apremilast 30 mg Crossover (XO) | Apremilast 30 mg /Apremilast 30 mg EE | Apremilast 20 mg /Apremilast 30 mg EE | Apremilast 30 mg /Apremilast 30 mg Second Escape (SE) | Apremilast 20 mg/Apremilast 30 mg SE |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 66 | 61 | 35 | 81 | 39 | 38 | 21 | 20 |
| Completed | 0 | 40 | 41 | 22 | 50 | 22 | 20 | 12 | 10 |
| Not completed | 0 | 26 | 20 | 13 | 31 | 17 | 18 | 9 | 10 |
| Withdrew: Adverse event | 0 | 5 | 2 | 2 | 6 | 2 | 2 | 3 | 1 |
| Withdrew: Lack of efficacy | 0 | 4 | 6 | 7 | 10 | 7 | 4 | 2 | 4 |
| Withdrew: Noncomplinace with study drug | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 11 | 11 | 1 | 12 | 7 | 5 | 3 | 3 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Miscellaneous | 0 | 5 | 1 | 2 | 0 | 1 | 5 | 0 | 1 |
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
| Percentage of Participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16 | 36.6 | 35.0 | 32.5 |
The BASFI is a composite score based on a self-administered survey of 10 questions using a 0 to 10 unit numerical rating scale (NRS) that assesses the degree of mobility and functional ability. The survey consists of 8 questions regarding function in AS and the last 2 reflect the ability to manage everyday life. The patient marks a box with an X on a 0 to 10 unit NRS for 10 questions; the left-hand box of 0 = easy; the right-hand box = impossible. The resulting 0 to 100 score is divided by 10 to give a final 0 to 10 BASFI score. The overall score is the mean of the 10 items and ranges from 0 to 10. A higher score correlates to reduced functional ability.
| Units on a Scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24 | -0.94 ± 0.136 | -1.11 ± 0.137 | -0.99 ± 0.138 |
The BASDAI is a composite score based on a participant self-administered survey of six questions measured using a 0 to 10 unit numerical rating scale (NRS) that assessed the participants' five major symptoms of AS: 1) fatigue; 2) spinal pain; 3) peripheral joint pain/swelling; 4) areas of localized tenderness; 5a) morning stiffness severity upon wakening; 5b) morning stiffness duration upon wakening. The participant was asked to mark the box with an X on a 0 to 10 unit NRS for each of the 6 questions. To give each of the five symptoms equal weighting, the mean of the two scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI score. A BASDAI score of 4 or greater was considered to be indicative of active AS disease.
| Units on a Scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24 | -1.21 ± 0.136 | -1.30 ± 0.136 | -1.18 ± 0.137 |
ASAS 20 was defined as achieving an improvement from baseline of ≥ 20% and ≥ 1 unit in at least 3 of 4 ASAS domains on a scale of 0 to 10 units and no worsening from baseline of ≥ 20% and ≥ 1 unit in the remaining ASAS domain on a scale of 0 to 10 units. The 4 ASAS domains are: 1. Patient Global Assessment of Disease (0 - 10 unit Numerical Rating Scale \[NRS\]); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = not active and the right-hand box = very active 2. Total Back Pain (0 to 10 unit NRS); participant marks a box with an X on a 0 - 10 unit NRS; the left-hand box of 0 = "no pain" and the right-hand box = "most severe pain" 3. Function (Bath AS Functional Index \[BASFI\] NRS 0 - 10 unit); participant provides a self-administered survey of 10 questions assessing for degree of mobility and functional ability 4. Inflammation domain is determined by the mean of 2 Bath AS Disease Activity Index NRS Questions #5 and #6 for morning stiffness) (0 - 10 unit)
| Percentage of Participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24 | 31.7 | 36.2 | 33.7 |
The ASQoL is a validated disease specific patient reported outcomes instrument to assess the impact of ankylosing spondylitis on the quality of life of individuals with emphasis on the ability of the person to fulfill his or her needs. It consisted of 18 items requesting a yes (score=1) or no (score=0) response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The summary score ranges 0-18 with higher scores indicating worse quality of life.
| Units on a Scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24 | -1.77 ± 0.278 | -1.50 ± 0.278 | -1.52 ± 0.281 |
The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) was a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores (based on US general population with mean of 50 and standard deviation of 10) were used in analyses. Higher scores indicate a higher level of functioning. The PCS encompasses physical functioning, role-physical, and bodily pain, as well as general health and vitality. A positive change from baseline score indicates an improvement
| Units on a Scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24 | 3.50 ± 0.553 | 3.46 ± 0.551 | 3.79 ± 0.559 |
The BASMI-Linear was designed to assess axial status (ie, cervical, dorsal and lumbar spine, hips, and pelvic soft tissue) and to define clinically significant changes in spinal movement. Five dimensions of movement (lateral lumbar flexion, tragus to wall, forward lumbar flexion, maximal intermalleolar distance, and cervical rotation) were measured and normalized on 0 to 10 unit NRS. The average of these scores was the total BASMI score, ranging from 0-10 with higher values indicating more severe limitation in spinal mobility.
| Units on a Scale | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24 | -0.19 ± 0.042 | -0.16 ± 0.043 | -0.13 ± 0.043 |
The Modified Stoke Ankylosing Spondylitis Spine Score is a scoring method used to determine the amount or degree of ankylosing spondylitis disease that is in the spine based on x-ray radiographs of the spine. The m-SASSS scores 0-3. 0 = No abnormality, 1 = Erosion, Sclerosis or Squaring, 2 = Syndesmophyte, 3 = Total bony Bridging at each Site. An increase in the m-SASSS indicated a worsening of AS disease.
| Units on a Scale | Apremilast 20 mg | Apremilast 30 mg | Placebo/Apremilast 30 mg | Apremilast 20 mg/ Apremilast 30 mg | Apremilast 20 mg/Apremilast 20 mg |
|---|---|---|---|---|---|
| Week 104 | 0.99 ± 3.018 | 0.65 ± 2.453 | 0.98 ± 3.768 | 0.82 ± 2.435 | 1.12 ± 3.417 |
| Week 260 | 3.14 ± 8.292 | 1.79 ± 6.997 | 1.92 ± 7.363 | 2.21 ± 5.959 | 3.83 ± 9.652 |
A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.
| Participants | Placebo | Apremilast 20 mg | Apremilast 30 mg |
|---|---|---|---|
| Any Treatment Emergent Adverse Event | 83 | 91 | 88 |
| Any Drug-related TEAE | 24 | 44 | 51 |
| Any Severe TEAE | 0 | 2 | 5 |
| Any Serious TEAE | 1 | 3 | 6 |
| Any Serious Drug-related TEAE | 0 | 0 | 3 |
| Any TEAE Leading to Drug Interruption | 14 | 13 | 14 |
| Any TEAE Leading to Drug Withdrawal | 7 | 11 | 13 |
| Any TEAE Leading to Death | 0 | 0 | 0 |
A TEAE was an adverse event (AE) with a start date on or after the date of the first dose of IP and no later than 28 days after the last dose of IP for participants who discontinued early. A serious AE = results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect; or constitutes an important medical event. The severity of AEs was assessed based on the following scale: Mild = asymptomatic or mild symptoms, clinical or diagnostic observations only; Moderate = symptoms cause moderate discomfort; Severe = symptoms causing severe pain discomfort.
| Participants | Apremilast 20 mg | Apremilast 20/30 mg | Apremilast 30 mg |
|---|---|---|---|
| Any Treatment Emergent Adverse Event | 114 | 47 | 239 |
| Any Severe TEAE | 5 | 8 | 23 |
| Any Serious TEAE | 12 | 8 | 41 |
| Any TEAE Leading to Drug Interruption | 22 | 11 | 51 |
| Any TEAE Leading to Drug Withdrawal | 18 | 4 | 34 |
| Any TEAE Leading to Death | 0 | 1 | 1 |
Collected over AEs were reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants. AEs were reported for the apremilast (APR) exposure period from Week 0 to Week 260, irrespective of when the APR started (Week 0, 16 or 24). The median duration of treatment was 24, 163, and 216 weeks in the Apremilast 20 mg, Apremilast 20/30 mg and Apremilast 30 mg treatment groups respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Weeks 0-24) Placebo-Controlled Phase | 0/164 (0%) | 1/164 (0.6%) | 37/164 (22.6%) |
| Apremilast 20 mg BID (Weeks 0-24) Placebo-Controlled Phase | 0/163 (0%) | 3/163 (1.8%) | 58/163 (35.6%) |
| Apremilast 30 mg BID (Weeks 0-24) Placebo-Controlled Phase | 0/163 (0%) | 6/163 (3.7%) | 57/163 (35%) |
| Apremilast 20 mg BID (APR Exposure Period) | 0/163 (0%) | 12/163 (7.4%) | 82/163 (50.3%) |
| Apremilast 20/30 mg BID (APR Exposure Period) | 1/72 (1.4%) | 8/72 (11.1%) | 38/72 (52.8%) |
| Apremilast 30 mg BID (APR Exposure Period) | 1/305 (0.3%) | 41/305 (13.4%) | 168/305 (55.1%) |
| Event | Placebo (Weeks 0-24) Placebo-Controlled Phase | Apremilast 20 mg BID (Weeks 0-24) Placebo-Controlled Phase | Apremilast 30 mg BID (Weeks 0-24) Placebo-Controlled Phase | Apremilast 20 mg BID (APR Exposure Period) | Apremilast 20/30 mg BID (APR Exposure Period) | Apremilast 30 mg BID (APR Exposure Period) |
|---|---|---|---|---|---|---|
| VertigoEar and labyrinth disorders | 0/164 | 0/163 | 1/163 | 0/163 | 1/72 | 1/305 |
| IridocyclitisEye disorders | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 1/305 |
| VomitingGastrointestinal disorders | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| Device failureGeneral disorders | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| CholelithiasisHepatobiliary disorders | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| Tibia fractureInjury, poisoning and procedural complications | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/164 | 0/163 | 0/163 | 1/163 | 1/72 | 1/305 |
| Ischaemic strokeNervous system disorders | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| Thrombotic cerebral infarctionNervous system disorders | 0/164 | 0/163 | 0/163 | 0/163 | 1/72 | 0/305 |
| Event | Placebo (Weeks 0-24) Placebo-Controlled Phase | Apremilast 20 mg BID (Weeks 0-24) Placebo-Controlled Phase | Apremilast 30 mg BID (Weeks 0-24) Placebo-Controlled Phase | Apremilast 20 mg BID (APR Exposure Period) | Apremilast 20/30 mg BID (APR Exposure Period) | Apremilast 30 mg BID (APR Exposure Period) |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 6/164 | 9/163 | 7/163 | 25/163 | 10/72 | 55/305 |
| DiarrhoeaGastrointestinal disorders | 7/164 | 22/163 | 17/163 | 26/163 | 4/72 | 38/305 |
| Upper respiratory tract infectionInfections and infestations | 8/164 | 7/163 | 8/163 | 17/163 | 8/72 | 32/305 |
| HeadacheNervous system disorders | 8/164 | 9/163 | 16/163 | 11/163 | 5/72 | 28/305 |
| NauseaGastrointestinal disorders | 7/164 | 10/163 | 14/163 | 13/163 | 6/72 | 28/305 |
| BronchitisInfections and infestations | 1/164 | 4/163 | 2/163 | 8/163 | 6/72 | 10/305 |
| SinusitisInfections and infestations | 1/164 | 2/163 | 1/163 | 7/163 | 5/72 | 10/305 |
| HypertensionVascular disorders | 4/164 | 4/163 | 6/163 | 6/163 | 2/72 | 21/305 |
| IridocyclitisEye disorders | 0/164 | 1/163 | 1/163 | 2/163 | 4/72 | 8/305 |
| Frequent bowel movementsGastrointestinal disorders | 2/164 | 2/163 | 3/163 | 3/163 | 4/72 | 3/305 |
The modified Intent to Treat (mITT) population included all participants who were randomized and received at least one dose of investigational product (IP); Five participants did not have a baseline SF-36 Physical Component Summary score.
| Age, Continuous(years) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 44.0 ± 12.89 | 45.2 ± 11.90 | 44.8 ± 11.75 | 44.7 ± 12.18 |
| Sex: Female, Male(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Female | 40 | 42 | 56 | 138 |
| Male | 124 | 121 | 107 | 352 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 1 | 7 |
| Not Hispanic or Latino | 158 | 159 | 162 | 479 |
| Unknown or Not Reported | 1 | 3 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 2 | 2 | 0 | 4 |
| Black or African American | 1 | 2 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| White | 158 | 154 | 158 | 470 |
| Other | 1 | 2 | 3 | 6 |
| Missing | 1 | 3 | 0 | 4 |
| Duration of Ankylosing Spondylitis (Lower Back Pain and Stiffness)(years) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 10.40 ± 10.375 | 11.06 ± 11.302 | 10.32 ± 9.887 | 10.60 ± 10.521 |
| Duration of Ankylosing Spondylitis(Participants) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| ≤ 2 years | 41 | 48 | 40 | 129 |
| >2 to ≤ 5 years | 29 | 23 | 26 | 78 |
| >5 to ≤ 10 years | 33 | 29 | 33 | 95 |
| >10 years | 61 | 63 | 64 | 188 |
| Baseline Bath Ankylosing Spondylitis Functional Index (BASFI) Score (0 - 10 NRS)(Units on a Scale) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 5.76 ± 2.194 | 5.75 ± 2.061 | 5.65 ± 2.100 | 5.72 ± 2.115 |
| Baseline Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score (0 - 10 NRS)(Units on a Scale) | Placebo | Apremilast 20 mg | Apremilast 30 mg | Total |
|---|---|---|---|---|
| Mean | 6.45 ± 1.319 | 6.46 ± 1.352 | 6.37 ± 1.357 | 6.42 ± 1.341 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 103 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from May 2012 to primary completion in Feb 2014, 21 months.
Results were first posted in Mar 2015, 1 year after primary completion.
Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 21 months is close to that.
Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apremilast